Market cap
$155.8M

Protara Therapeutics Inc. (TARA) is a Biotechnology: Biological Products (No Diagnostic Substances) company listed on NASDAQ. In the last 30 days Quantisnow tracked 3 wire items for TARA, including 2 SEC filings and 1 earnings update. The most recent was published Nov 6, 2026.

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.

TARA rankings

Financial highlights

Full financials
Net income, TTM
-$78.44M
Cash
$25.15M

For the twelve months ended Sep 30, 2026, from SEC filings. Not investment advice.

News · 26 weeks25+200%
2026-05-24: 22026-05-31: 12026-06-07: 02026-06-14: 92026-06-21: 02026-06-28: 22026-07-05: 12026-07-12: 02026-07-19: 02026-07-26: 02026-08-02: 02026-08-09: 52026-08-16: 02026-08-23: 02026-08-30: 02026-09-06: 12026-09-13: 02026-09-20: 02026-09-27: 02026-10-04: 02026-10-11: 12026-10-18: 02026-10-25: 02026-11-01: 32026-11-08: 02026-11-15: 0
2026-05-242026-11-15
Mix590d
  • Other2(40%)
  • SEC Filings2(40%)
  • Earnings1(20%)
Activity · 52 weeks8245 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news

Latest news

25 items

TARA FAQ

10 questions
  • What does Protara Therapeutics Inc. do?
    Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May...
  • What is the latest news on TARA?
    In the last 30 days Quantisnow tracked 3 wire items for TARA: 2 SEC filings and 1 earnings update. The most recent was published on November 6, 2026.
  • Is TARA profitable?
    No. Protara Therapeutics Inc. reported a net loss of $78.44M for the twelve months ended Sep 30, 2026.
  • How much cash and debt does TARA have?
    Protara Therapeutics Inc. reported $25.15M in cash and cash equivalents on its most recent balance sheet in SEC filings.
  • Where does TARA stock trade?
    Protara Therapeutics Inc. (TARA) is listed on NASDAQ.
  • What sector and industry is TARA in?
    Protara Therapeutics Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.
  • When did Protara Therapeutics Inc. go public?
    Protara Therapeutics Inc. (TARA) completed its IPO in 2014.
  • What are analysts saying about TARA?
    Protara Therapeutics Inc. has had 6 recent analyst actions on file. The most recent action was from Analyst: Overweight with a $27.00 price target on 2026-03-04. Recent price targets range from $12.00 to $34.00.
  • What companies are similar to TARA?
    Notable peers in the same industry include MRNA (Moderna Inc.), AMGN (Amgen Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), GILD (Gilead Sciences Inc.). Compare TARA side-by-side with any of them on Quantisnow.
  • How can I track TARA on Quantisnow?
    Quantisnow aggregates Protara Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow TARA to receive live email and push alerts on every new disclosure.